AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys

Journal of Biotechnology

Volumn 144, Issue 2, 2009, Pages 135-141

  Boado, Ruben J ^a,b   Hui, Eric K W ^a   Lu, Jeff Zhiqiang ^a   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Iduronidase; Insulin receptor; Primate; Trojan horse

Indexed keywords

BLOOD-BRAIN BARRIER; IDURONIDASE; INSULIN RECEPTOR; PRIMATE; TROJAN HORSE;

BLOOD; ENZYMES; GENETIC ENGINEERING; GLUCOSE; INSULIN; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; PLASMAS; SAFETY ENGINEERING;

ENZYME ACTIVITY;

AGT 181; HYBRID PROTEIN; INSULIN RECEPTOR; LEVO IDURONIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CHO CELL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GLYCEMIC CONTROL; IMMUNE RESPONSE; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY;

ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE; HUMANS; IDURONIDASE; MACACA MULATTA; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EQUIDAE; MACACA MULATTA; PRIMATES;

EID: 70350236476     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2009.08.019     Document Type: Article

References (17)

1. Boado R.J., Zhang Y., and Pardridge W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 97 (2007) 1376-1386
2. Boado R.J., Zhang Y., Xia C.F., Wang Y., and Pardridge W.M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 99 (2008) 475-484
3. Brady R.O., and Schiffmann R. Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 3 (2004) 752-756
4. Cheng S.H., and Smith A.E. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 10 (2003) 1275-1281
5. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., and Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123 (2009) 229-240
6. Daniel P.M., Love E.R., and Pratt O.E. Insulin and the way the brain handles glucose. J. Neurochem. 25 (1975) 471-476
7. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., Scott D.W., and Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112 (2008) 3303-3311
8. Garman R.H. Evaluation of large-sized brains for neurotoxic endpoints. Toxicol. Pathol. 31 Suppl. (2003) 32-43
9. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr. Suppl. 94 (2005) 58-60 (discussion 57)
10. Muenzer J., and Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N. Engl. J. Med. 350 (2004) 1932-1934
11. Neufeld E.F. Lysosomal storage diseases. Annu. Rev. Biochem. 60 (1991) 257-280
12. Pardridge W.M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 19 (2008) 1327-1338
13. Pardridge W.M., and Boado R.J. Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-gdnf fusion protein for targeted blood-brain barrier delivery. Pharm. Res. 10 (2009) 2227-2236
14. Pardridge W.M., Kang Y.S., Buciak J.L., and Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12 (1995) 807-816
15. Scott H.S., Anson D.S., Orsborn A.M., Nelson P.V., Clements P.R., Morris C.P., and Hopwood J.J. Human alpha-l-iduronidase: cDNA isolation and expression. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 9695-9699
16. Tsukimura T., Tajima Y., Kawashima I., Fukushige T., Kanzaki T., Kanekura T., Ikekita M., Sugawara K., Suzuki T., Togawa T., and Sakuraba H. Uptake of a recombinant human alpha-l-iduronidase (laronidase) by cultured fibroblasts and osteoblasts. Biol. Pharm. Bull. 31 (2008) 1691-1695
17. Wraith J.E. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J. Inherit. Metab. Dis. 24 (2001) 245-250